Research Interests
At present, the research group is mainly engaged in the research and development of new drugs for the treatment of malignant tumors, especially the R&D of anti-tumor molecular targeted drugs and anti-tumor immunotherapy small molecule drugs.
Specifically, the group is working on:
(1) R&D of novel small molecule inhibitors for immune checkpoint.
(2) R&D of tumor immunotherapy diagnostic reagent based on PD-L1 target.
(3) R&D of anti-tumor immunotherapeutic agents that specifically target tumor tissue.
(4) R&D of small molecule anticancer agents based on PROTACs technology.
(5) R&D of multi-functional anti-tumor targeted drugs based on targeting tumor stem cells.
